Derivative works — US Patent 12447128

Defensive Disclosure: Formulations of Enzalutamide (US12447128)

This document outlines derivative variations of the inventions claimed in US Patent 12447128 ("Formulations of enzalutamide"), intended for defensive publication. The goal is to establish prior art that renders future incremental improvements by competitors obvious or non-novel, specifically targeting the core claims related to amorphous enzalutamide solid dispersions, their manufacturing, and performance characteristics.

Derivative Variations

1. Material & Component Substitution

Derivative 1.1: Polymer Blend Amorphous Dispersion

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a polymer blend comprising hydroxypropyl methylcellulose acetate succinate (HPMCAS) and a thermally stable, water-soluble, non-ionic cellulosic polymer such as hypromellose (HPMC) at a weight ratio of 2:1 (HPMCAS:HPMC). The enzalutamide loading in the total polymer matrix is 60% w/w. This blend is prepared by co-dissolving enzalutamide, HPMCAS-M grade (e.g., Shin-Etsu AQOAT® HPMCAS-MG), and HPMC E5LV (e.g., Dow Methocel™ E5 LV) in a common solvent system of acetone:ethanol (1:1 v/v) at a concentration of 5% w/v total solids. The solution is then spray-dried using a laboratory-scale spray dryer with an inlet temperature of 90°C, a solvent feed rate of 25 mL/min, and an atomizing airflow of 0.7 bar. The resulting amorphous solid dispersion exhibits enhanced physical stability and dissolution performance compared to single-polymer systems, achieving a mean AUC 0-7 days greater than 150 µg·hr/ml at a 160 mg oral dose in humans and containing less than 30% by weight of lipophilic microphase-forming materials. The HPMC contributes to improved processability and matrix integrity, while HPMCAS maintains supersaturation.

graph TD
    A[Enzalutamide (API)] --> C{Dissolve in Common Solvent}
    B1[HPMCAS-M Polymer] --> C
    B2[HPMC E5LV Polymer] --> C
    C --> D[Homogeneous Solution]
    D --> E{Spray Drying}
    E --> F[Amorphous Solid Dispersion (ASD)]
    F --> G[Composition (Tablet/Capsule)]
    G --> H{Oral Administration}
    H --> I[Enhanced AUC/Cmax in vivo]

Derivative 1.2: Mesoporous Silica Carrier for Amorphous Enzalutamide

Enabling Description:
A pharmaceutical composition comprising enzalutamide (at least 60% amorphous) adsorbed onto a mesoporous silica carrier (e.g., SBA-15 or MCM-41 with pore size 2-10 nm) and subsequently encapsulated within a polymer matrix of polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA64). Enzalutamide is loaded into the mesoporous silica via incipient wetness impregnation from an ethanolic solution, followed by solvent evaporation to yield amorphous enzalutamide within the silica pores. This drug-loaded silica is then blended with PVP-VA64 powder at a 1:1 (w/w) ratio (drug-loaded silica:polymer) and processed via hot-melt extrusion at 150°C to form a final solid dispersion. The mesoporous silica acts as an inert scaffold for stabilizing the amorphous drug, and the polymer provides concentration enhancement and maintains stability. The final formulation, once milled, maintains enzalutamide in an amorphous state, achieves a mean Cmax greater than 2 µg/ml at a 160 mg oral dose, and contains less than 30% lipophilic microphase-forming materials.

graph TD
    A[Enzalutamide Solution] --> B{Impregnate Mesoporous Silica (SBA-15)}
    B --> C[Evaporate Solvent]
    C --> D[Amorphous Enzalutamide in Silica Pores]
    D --> E{Blend with PVP-VA64 Polymer}
    E --> F{Hot-Melt Extrusion (HME)}
    F --> G[SDD with Silica Carrier]
    G --> H[Composition (Milled Powder)]
    H --> I{Oral Administration}
    I --> J[Enhanced Cmax in vivo]

Derivative 1.3: Biodegradable Polymer Dispersion for Sustained Release

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a biodegradable polyester polymer, specifically poly(lactic-co-glycolic acid) (PLGA) with a lactic:glycolic acid ratio of 75:25 and a molecular weight of 30-60 kDa. The solid dispersion is prepared by co-dissolving enzalutamide and PLGA in a common solvent (e.g., dichloromethane) and forming microparticles via emulsion-solvent evaporation. The solution is emulsified in an aqueous phase containing a stabilizer (e.g., polyvinyl alcohol), followed by solvent removal to yield amorphous enzalutamide-PLGA microparticles. These microparticles provide sustained release capabilities in addition to enhanced solubility due to the amorphous state, suitable for extended dosing intervals. The resulting solid dispersion maintains amorphous enzalutamide, delivers an AUC 0-7 days greater than 150 µg·hr/ml, and is formulated with less than 30% by weight of lipophilic microphase-forming materials, potentially enabling reduced frequency dosing.

graph TD
    A[Enzalutamide] --> C{Co-dissolve in DCM}
    B[PLGA Polymer] --> C
    C --> D[DCM Solution]
    D --> E{Emulsify in Aqueous PVA}
    E --> F[Emulsion Droplets]
    F --> G{Solvent Evaporation}
    G --> H[Amorphous Enzalutamide-PLGA Microparticles]
    H --> I[Composition (Capsule/Injection)]
    I --> J{Administration}
    J --> K[Sustained Release & Enhanced AUC]

Derivative 1.4: Cryo-Milled Amorphous Enzalutamide with a Poloxamer Matrix

Enabling Description:
A pharmaceutical composition comprising enzalutamide (at least 60% amorphous) and a poloxamer, specifically Poloxamer 407 (Kolliphor® P 407). Enzalutamide is micronized via cryogenic milling at liquid nitrogen temperatures to induce amorphicity while minimizing degradation. The cryo-milled amorphous enzalutamide powder is then hot-melt extruded with Poloxamer 407 at a 1:2 (enzalutamide:Poloxamer) ratio at a temperature of 80°C, forming a eutectic or solid solution. Poloxamer 407 acts as both a solid dispersion matrix and a surfactant, ensuring rapid wetting and solubilization. The resulting solid dispersion, characterized by a rapid dissolution onset, provides a mean Cmax greater than 2 µg/ml at a 160 mg oral dose, with the Poloxamer content explicitly controlled to be less than 30% by weight of total lipophilic microphase-forming materials.

graph TD
    A[Crystalline Enzalutamide] --> B{Cryogenic Milling}
    B --> C[Amorphous Enzalutamide Powder]
    D[Poloxamer 407] --> E{Hot-Melt Extrusion}
    C --> E
    E --> F[Amorphous Solid Dispersion (ASD)]
    F --> G[Composition (Rapid-Dissolve Tablet)]
    G --> H{Oral Administration}
    H --> I[Rapid Cmax & Enhanced Bioavailability]

2. Operational Parameter Expansion

Derivative 2.1: Supercritical Fluid-Assisted Anti-Solvent Precipitation

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide and hydroxypropyl methylcellulose acetate succinate (HPMCAS-L grade) where enzalutamide is at least 60% amorphous and the dispersion contains less than 30% by weight of lipophilic microphase-forming materials. Enzalutamide and HPMCAS are co-dissolved in a suitable organic solvent (e.g., dimethyl sulfoxide, DMSO) to form a concentrated solution. This solution is then rapidly injected into a continuous flow of supercritical carbon dioxide (scCO2) at 40°C and 150 bar, acting as an anti-solvent. The rapid reduction in solvent power due to scCO2 induces immediate precipitation of an amorphous solid dispersion with controlled particle size (<10 µm). The scCO2 simultaneously extracts the organic solvent, resulting in a high-purity, solvent-free amorphous solid dispersion suitable for direct compression into tablets. This process ensures high amorphicity and fine particle size without thermal degradation.

graph TD
    A[Enzalutamide + HPMCAS-L] --> B{Dissolve in DMSO}
    B --> C[Solution A]
    D[Supercritical CO2 (40°C, 150 bar)] --> E{Anti-Solvent Precipitation Chamber}
    C --> E
    E --> F[Amorphous SDD (Microparticles)]
    F --> G{CO2 Separation & Solvent Recovery}
    G --> H[Dry Amorphous Solid Dispersion]
    H --> I[Further Processing (e.g., Tableting)]

Derivative 2.2: Continuous Twin-Screw Extrusion with Inline Analytics

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide (at least 60% amorphous) and a concentration-enhancing polymer (e.g., Soluplus®) using continuous twin-screw hot-melt extrusion. Powdered enzalutamide and Soluplus are gravimetrically fed into a twin-screw extruder. The extruder barrel temperature profile is precisely controlled (e.g., 140°C-180°C-170°C). Residence time in the extruder is maintained at approximately 45 seconds to ensure complete melting and mixing. An inline Near-Infrared (NIR) spectroscopic probe positioned at the die exit provides real-time monitoring of enzalutamide's amorphous content and dispersion homogeneity. Feedback control loops adjust extrusion parameters (e.g., screw speed, feeder rate) to maintain consistent product quality, ensuring >60% amorphous enzalutamide and a final product containing less than 30% by weight of lipophilic microphase-forming materials, thereby optimizing Cmax and AUC.

graph TD
    A[Enzalutamide Powder] --> B{Gravimetric Feeder}
    C[Soluplus Powder] --> B
    B --> D[Twin-Screw Extruder (Temp. Profile)]
    D --> E[Molten Mixture]
    E --> F{NIR Spectrometer (Inline)}
    F -- Real-time Amorphicity/Homogeneity --> G{Feedback Control System}
    G -- Adjusts Parameters --> B
    G -- Adjusts Parameters --> D
    F --> H[Extrudate (Solid Dispersion)]
    H --> I[Milling/Pelletizing]
    I --> J[Final Amorphous Solid Dispersion]

Derivative 2.3: Ultrasonic Atomization for Nano-Dispersion Formation

Enabling Description:
A method for manufacturing a solid dispersion of enzalutamide (at least 90% amorphous) and polyvinylpyrrolidone (PVP K30) where the dispersion contains less than 30% by weight of lipophilic microphase-forming materials. A solution of enzalutamide and PVP K30 (1:3 w/w ratio) in a volatile solvent like ethanol is prepared. This solution is fed to an ultrasonic nozzle operating at a frequency of 120 kHz, which generates extremely fine droplets (e.g., 5-20 µm diameter) at ambient temperature. These droplets are then subjected to gentle nitrogen gas flow in a drying chamber for rapid solvent evaporation, yielding a nano-sized amorphous solid dispersion powder. The low-temperature, fine-droplet formation minimizes thermal degradation and accelerates solvent removal, resulting in a highly amorphous and stable product with superior dissolution rates and expected Cmax/AUC values.

graph TD
    A[Enzalutamide + PVP K30] --> B{Dissolve in Ethanol}
    B --> C[Solution Feed]
    D[Ultrasonic Nozzle (120 kHz)] --> E[Ultra-fine Droplets]
    C --> D
    E --> F{Drying Chamber (Nitrogen Gas)}
    F --> G[Nano-sized Amorphous SDD]
    G --> H[Collection & Further Processing]
    H --> I[Enhanced Dissolution/Bioavailability]

3. Cross-Domain Application

Derivative 3.1: AgTech - Controlled Release Herbicide Formulation

Enabling Description:
A formulation for agricultural application comprising an amorphous solid dispersion of a poorly soluble herbicide (e.g., atrazine) and a plant-compatible polymer (e.g., lignin-based polymer or starch acetate). The herbicide, in an at least 60% amorphous state, is dispersed within the polymer matrix. This is achieved by co-dissolving the herbicide and polymer in a suitable solvent (e.g., ethyl acetate) and then spray-drying the solution. The resulting amorphous solid dispersion microparticles (e.g., 50-200 µm) are designed for improved foliar uptake and controlled release in agricultural environments, minimizing runoff and extending efficacy. This formulation delivers active ingredient to target weeds with enhanced bioavailability, mimicking the improved absorption observed for enzalutamide in human systems. Lipophilic additives are kept below 30% to maintain environmental compatibility.

graph TD
    A[Poorly Soluble Herbicide (API)] --> C{Co-dissolve in Solvent}
    B[Lignin-based Polymer] --> C
    C --> D[Herbicide-Polymer Solution]
    D --> E{Spray Drying}
    E --> F[Amorphous Herbicide Microparticles (SDD)]
    F --> G[Agrochemical Formulation (e.g., Liquid Suspension)]
    G --> H{Foliar/Soil Application}
    H --> I[Controlled Release & Enhanced Bioavailability in Plants]

Derivative 3.2: Veterinary Oncology - Palatable Tablet for Canine Prostate Cancer

Enabling Description:
A pharmaceutical composition for veterinary use, specifically treating canine prostate cancer, comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a veterinary-acceptable polymer (e.g., hydroxypropyl cellulose, HPC) combined with palatability enhancers (e.g., beef flavor, saccharin). Enzalutamide and HPC are co-dissolved in a common solvent and spray-dried to form the amorphous solid dispersion. This dispersion is then blended with flavorants and other excipients (e.g., microcrystalline cellulose, magnesium stearate) and directly compressed into palatable, chewable tablets of suitable size for large breed dogs (e.g., 100-300 mg enzalutamide per tablet). This formulation aims to improve enzalutamide's oral bioavailability in canines, leveraging the dissolution enhancement of the amorphous solid dispersion, thereby reducing the number of doses required and improving owner compliance, similar to the human therapeutic benefit. Lipophilic microphase-forming materials are maintained below 30% by weight.

graph TD
    A[Enzalutamide (API)] --> C{Dissolve & Spray Dry}
    B[HPC Polymer] --> C
    C --> D[Amorphous Enzalutamide SDD]
    E[Beef Flavor] --> F{Blend & Compress}
    G[Saccharin] --> F
    D --> F
    F --> H[Palatable Chewable Tablet]
    H --> I{Oral Administration to Canine}
    I --> J[Improved Bioavailability for Canine Cancer Treatment]

Derivative 3.3: Functional Coatings - UV-Protective Polymer Films

Enabling Description:
A polymer film for protective coatings comprising an amorphous solid dispersion of a poorly soluble organic UV-absorber (e.g., oxybenzone derivative) and a transparent polymer matrix (e.g., poly(methyl methacrylate), PMMA). The UV-absorber is rendered at least 60% amorphous by co-dissolving it with PMMA in a volatile solvent (e.g., toluene) and spray-coating this solution onto a substrate or casting it as a film. The amorphous dispersion provides enhanced molecular dispersion of the UV-absorber within the film, leading to improved transparency and more effective, uniform UV protection compared to crystalline forms. This technology finds application in durable exterior coatings, automotive finishes, or transparent packaging, leveraging the principle of enhanced molecular dispersion and stability of amorphous compounds in a polymer matrix. Lipophilic additives, if any, are kept below 30% by weight to maintain optical clarity and film integrity.

graph TD
    A[Poorly Soluble UV-Absorber] --> C{Co-dissolve in Toluene}
    B[PMMA Polymer] --> C
    C --> D[UV-Absorber-PMMA Solution]
    D --> E{Spray Coating/Film Casting}
    E --> F[Amorphous SDD within Polymer Film]
    F --> G[Cured UV-Protective Film]
    G --> H{Application (e.g., Automotive Coating)}
    H --> I[Enhanced & Uniform UV Protection]

4. Integration with Emerging Tech

Derivative 4.1: AI-Driven Formulation Optimization

Enabling Description:
A method for designing and manufacturing amorphous enzalutamide solid dispersions with optimal in vivo performance characteristics (AUC 0-7 days > 150 µg·hr/ml, Cmax > 2 µg·hr/ml) using an AI-driven optimization platform. The platform integrates a machine learning model trained on a large dataset of enzalutamide-polymer interactions, processing parameters (spray-drying, HME), and resulting in vitro dissolution/in vivo pharmacokinetic data. Users input desired target AUC/Cmax profiles and constraints (e.g., specific polymers, dosage form, manufacturing equipment limits). The AI algorithm predicts optimal polymer type(s), polymer:drug ratio, solvent system, and critical process parameters (e.g., inlet temperature, feed rate, screw speed, barrel temperature profile) to achieve the target performance while ensuring enzalutamide is at least 60% amorphous and lipophilic microphase-forming materials are below 30%. This system also suggests combinations with novel excipients and predicts their interaction.

graph TD
    A[Input: Target AUC/Cmax, Constraints] --> B{AI Optimization Platform}
    B --> C[Machine Learning Model]
    D[Historical Formulation Data] --> C
    E[Polymer-Drug Interaction Database] --> C
    C --> F[Predicted Optimal Formulation Parameters]
    F --> G[Manufacturing Process (e.g., Spray Drying)]
    G --> H[Amorphous Enzalutamide SDD]
    H --> I[Quality Control (Verify AUC/Cmax)]
    I -- Feedback Loop --> C

Derivative 4.2: IoT-Monitored Smart Packaging for Stability Assurance

Enabling Description:
A pharmaceutical dosage unit (e.g., tablet blister pack) containing an amorphous solid dispersion of enzalutamide (at least 60% amorphous) and HPMCAS, integrated with passive IoT sensors for real-time monitoring of environmental conditions and formulation stability. Each blister cavity or unit-dose pouch contains a miniature, wireless, non-invasive sensor that continuously records temperature and relative humidity. Data from these sensors is transmitted to a central gateway or smartphone app via low-power Bluetooth or NFC. An onboard micro-controller analyzes this data against pre-defined stability thresholds (e.g., critical humidity levels, excursions above glass transition temperature). Alerts are generated if conditions threaten the amorphous state of enzalutamide. This system ensures product integrity throughout the supply chain and at the patient's home, validating that the formulation retains its optimal AUC/Cmax characteristics and amorphous content. Data about environmental conditions is automatically stored, for example, on a blockchain.

graph TD
    A[Amorphous Enzalutamide SDD Tablet] --> B[Blister Pack / Unit-Dose Pouch]
    B --> C[Integrated IoT Sensor]
    C -- Temp/RH Data --> D{Wireless Gateway / Smartphone}
    D -- Data Stream --> E[Cloud Analytics Platform]
    E -- Alerts/Warnings --> F[Patient/Pharmacist App]
    E -- Stability Record --> G[Blockchain Ledger]
    G --> H[Immutable Audit Trail]
    subgraph Monitoring & Data Flow
        C --- D
        D --- E
    end

Derivative 4.3: Blockchain for Supply Chain & Authenticity Verification

Enabling Description:
A system for ensuring the authenticity and manufacturing provenance of amorphous enzalutamide solid dispersion pharmaceutical compositions (at least 60% amorphous, <30% lipophilic materials). Each batch of spray-dried or hot-melt extruded amorphous enzalutamide-polymer dispersion is assigned a unique batch identifier, cryptographically hashed, and recorded on a private blockchain ledger. Key manufacturing parameters (e.g., spray dryer inlet/outlet temperatures, solvent type, polymer:drug ratio, inline NIR amorphicity verification, final purity, packaging date) are also timestamped and recorded. Subsequent events like packaging, shipment, distribution to pharmacies, and dispensing are similarly recorded. Consumers or regulators can scan a QR code on the final dosage form, which queries the blockchain to verify its origin, manufacturing conditions, and confirm it corresponds to a genuine batch of the amorphous enzalutamide formulation, thereby mitigating counterfeiting and ensuring product quality (e.g., anticipated AUC/Cmax).

sequenceDiagram
    participant Manufacturer
    participant QC_Lab
    participant Distributor
    participant Pharmacy
    participant Patient
    participant Blockchain

    Manufacturer->>Blockchain: Record Batch ID & Mfg Params (Amorphicity, Polymer Ratio)
    QC_Lab->>Blockchain: Record Release Test Results (Purity, Dissolution, AUC/Cmax)
    Distributor->>Blockchain: Record Shipping & Logistics Data
    Pharmacy->>Blockchain: Record Receipt & Inventory Updates
    Patient->>Patient: Scan QR Code on Packaging
    Patient->>Blockchain: Query Batch ID for Authenticity
    Blockchain-->>Patient: Return Verified Mfg & Quality Data

5. The "Inverse" or Failure Mode

Derivative 5.1: Rapid Degrading Amorphous Dispersion for Environmental Safety

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a rapidly biodegradable, water-soluble polymer (e.g., polyethylene glycol-co-polycaprolactone, PEG-PCL, or specific grades of polylactide, PLA) designed for accelerated environmental degradation. The dispersion is manufactured via solvent evaporation, forming microparticles where enzalutamide is encapsulated. This formulation is engineered to provide therapeutic benefits upon oral administration (AUC 0-7 days > 150 µg·hr/ml) but, if inadvertently released into the environment (e.g., wastewater), the polymer matrix rapidly hydrolyzes under typical environmental conditions (e.g., soil pH, microbial activity), leading to accelerated degradation of both the polymer and enzalutamide into inert byproducts within days, rather than weeks or months. This minimizes ecological impact. Lipophilic microphase-forming materials are intentionally omitted or kept below 5% to facilitate rapid breakdown and reduce environmental persistence.

graph TD
    A[Enzalutamide] --> C{Co-dissolve in Solvent}
    B[PEG-PCL Polymer] --> C
    C --> D[Solution]
    D --> E{Solvent Evaporation/Microparticle Formation}
    E --> F[Rapidly Degrading Amorphous SDD]
    F --> G[Oral Administration (Therapeutic Effect)]
    G --> H{Environmental Release (Accidental)}
    H --> I[Rapid Polymer Hydrolysis]
    I --> J[Accelerated Enzalutamide Degradation]
    J --> K[Inert Byproducts (Environmental Safety)]

Derivative 5.2: Low-Dose, Limited-Functionality Formulation for Diagnostic Tracing

Enabling Description:
A pharmaceutical composition comprising a sub-therapeutic dose (e.g., 10 mg) of enzalutamide, where the enzalutamide is at least 60% amorphous, in a solid dispersion with a concentration-enhancing polymer (e.g., HPMC). This formulation is specifically designed for diagnostic purposes, such as tracing enzalutamide distribution or receptor occupancy via PET imaging (using a radiolabeled enzalutamide analog) or pharmacokinetic profiling in sensitive patient populations (e.g., early-stage clinical trials for dose ranging). The amorphous solid dispersion ensures rapid dissolution and absorption even at low doses, allowing for precise pharmacokinetic assessment without eliciting full therapeutic or adverse effects. The formulation deliberately avoids high drug loading or maximal concentration enhancement to operate in a "limited-functionality" mode, focusing on detection and distribution rather than full therapeutic impact. Lipophilic microphase-forming materials are less than 30% by weight.

graph TD
    A[Enzalutamide (Low Dose)] --> C{Co-dissolve & Spray Dry}
    B[HPMC Polymer] --> C
    C --> D[Low-Dose Amorphous SDD]
    D --> E[Diagnostic Capsule/Tablet]
    E --> F{Oral Administration (Diagnostic Use)}
    F --> G[Rapid Absorption for Tracing]
    G --> H[Imaging/Pharmacokinetic Profiling (Limited Therapeutic Effect)]

Derivative 5.3: Controlled Release with Triggered Fail-Safe Excretion

Enabling Description:
A pharmaceutical composition comprising a solid dispersion of enzalutamide (at least 60% amorphous) and a concentration-enhancing polymer (e.g., HPMCAS), further encapsulated within an enteric-coated system that includes an excipient designed for triggered rapid excretion. The enzalutamide-polymer dispersion provides the desired AUC/Cmax upon normal gastrointestinal transit. However, in the event of accidental overdose or adverse reaction, administration of a specific counter-agent (e.g., a high-pH solution or a chelating agent) triggers the rapid disintegration of the enteric coating and/or the polymer matrix, leading to rapid and controlled release of enzalutamide into the intestinal lumen, followed by accelerated fecal excretion through the action of a co-formulated, mild, non-toxic laxative agent (e.g., magnesium citrate, PEG 3350) incorporated into the outer layer. This "fail-safe" mechanism reduces systemic exposure in emergency situations. Lipophilic microphase-forming materials are kept below 30%.

stateDiagram
    [*] --> Formulated_SDD
    Formulated_SDD --> In_Digestive_Tract : Oral Administration
    In_Digestive_Tract --> Therapeutic_Release : Normal Transit (Optimal AUC/Cmax)
    In_Digestive_Tract --> Fail_Safe_Mode : Accidental Overdose / Adverse Event
    Fail_Safe_Mode --> Trigger_Administered : Counter-Agent (e.g., High pH Solution)
    Trigger_Administered --> Rapid_Disintegration : Enteric Coat & Matrix Breakdown
    Rapid_Disintegration --> Accelerated_Excretion : Enhanced Fecal Clearance
    Accelerated_Excretion --> [*]

Combination Prior Art Scenarios

These scenarios combine the teachings of US Patent 12447128 with existing open-source standards or widely available knowledge, rendering specific applications or refinements obvious.

US12447128 + ICH Q8/Q9/Q10 (Quality by Design Guidelines):
A person skilled in the art, following the principles of Quality by Design (QbD) as outlined in ICH guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System), would find it obvious to apply a systematic approach to optimize the manufacturing process (Claim 11) for amorphous enzalutamide solid dispersions. This would involve using a Design of Experiments (DoE) approach to identify critical process parameters (CPPs) for spray-drying (e.g., inlet/outlet temperatures, feed rate, atomization pressure) and critical material attributes (CMAs) for enzalutamide and the polymer (e.g., particle size, molecular weight, crystallinity), to achieve a predefined target product profile (TPP) for the resulting amorphous solid dispersion. The use of Process Analytical Technology (PAT) tools (e.g., inline NIR for amorphicity, particle size distribution, moisture content) would be routinely implemented to monitor and control these CPPs in real-time, ensuring consistent quality, including the desired amorphous content (>60%) and dissolution performance (MDC, AUC), as well as controlling lipophilic microphase-forming materials (<30%).
US12447128 + Open-source Population PK/PD Modeling (e.g., NONMEM, R-packages like 'mrgsolve'):
It would be obvious to a person skilled in the art to use established population pharmacokinetic/pharmacodynamic (PK/PD) modeling techniques, readily available through open-source software (e.g., NONMEM, or R-packages such as 'mrgsolve' and 'nlmixr'), to refine and predict the in vivo performance (AUC 0-7 days > 150 µg·hr/ml, Cmax > 2 µg/ml) of amorphous enzalutamide solid dispersions (Claims 1 & 17). This involves collecting sparse or full PK data from initial human studies (e.g., those described in Example 15 of US12447128), fitting these data to population PK models, and then using simulations to predict optimal dosing regimens, inter-patient variability, and the impact of formulation changes (e.g., different polymer ratios, particle sizes of the amorphous dispersion) on systemic exposure and therapeutic outcomes. This approach allows for efficient prediction of desired in vivo characteristics without extensive clinical trials for every formulation variant.
US12447128 + Open-source Computational Chemistry & Materials Science Libraries (e.g., LAMMPS, RDKit, MDAnalysis):
Given the understanding of amorphous solid dispersions for improving solubility, a person skilled in the art would find it obvious to utilize open-source computational chemistry and materials science tools to predict and optimize the stability and performance of enzalutamide-polymer amorphous solid dispersions (Claims 1 & 17). Specifically, molecular dynamics (MD) simulations using software like LAMMPS (Large-scale Atomic/Molecular Massively Parallel Simulator) could be employed to model the drug-polymer interactions at an atomic level, predicting glass transition temperatures (Tg), miscibility, and potential for recrystallization. Cheminformatics libraries like RDKit could be used to screen a vast array of potential concentration-enhancing polymers based on predicted compatibility with enzalutamide's chemical structure. This computational approach would accelerate the selection of optimal polymers and formulation parameters, reducing the need for extensive empirical testing to achieve stable amorphous forms, desired AUC/Cmax, and maintain the low content of lipophilic microphase-forming materials.